Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Natco pharma partner...

    Natco pharma partner Mylan gets USFDA nod for multiple sclerosis injection

    Written by Ruby Khatun Khatun Published On 2017-10-04T10:55:58+05:30  |  Updated On 18 Aug 2021 3:46 PM IST

    New Delhi: The US Food and Drug Administration has granted approval to drug major Natco Pharma's marketing partner Mylan's Glatiramer Acetate injection used for the treatment of relapsing forms of multiple sclerosis(MS).


    The approval is granted to the drug in strengths of 40 mg/ml and 20 mg/ml and the product is the substitutable generic version of Teva's Copaxone, Natco Pharma said in a regulatory filing today.


    The launch plans for both will be communicated shortly after concurring with its partner Mylan, it added.


    Natco Pharma said Copaxone is the most prescribed MS treatment for relapsing forms in the United States with brand sales for the 20 mg/ml dose at approximately USD 700 million and for the 40 mg/ml dose at nearly USD 3.64 billion for the 12 months to July 31, according to Quintiles IMS.


    Close to 4,00,000 individuals in the US have MS and relapsing MS accounts for 85 percent of initial diagnosis, it added.



    ApprovesCopaxoneEpiPenFDAgenericgeneric versionGlatiramer Acetate Injectionindian pharma newsmultiple sclerosismultiple sclerosis treatmentMylanNatco pharmapharma newspharma news indiaPharmaceuticalsTevaU.S. Food and Drug Administration
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok